Global Antibody Drug Conjugates Market: Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global antibody drug conjugates market over the forecast period. North America is estimated to hold 37.7% of the market share in 2023. The North American antibody drug conjugates market is expected to witness significant growth in the coming years, driven by new product launches or approvals. For instance, in April 2021, ADC Therapeutics SA, a next-generation biotechnology company focused on oncology, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNLONTA (Loncastuximab Tesirinelpyl) for the treatment of relapsed or refractory large B-cell lymphoma. ZYNLONTA, a CD19-targeted antibody-drug conjugate, received accelerated approval from the U.S. FDA based on its overall response rate.
Antibody Drug Conjugates Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients